Earnings per share for the last twelve months: Regulus Therapeutics Inc (RGLS)
Regulus Therapeutics (RGLS) aims for leadership in the kidney therapy niche by advancing unique RNA-based drugs. The current trailing twelve-month EPS reflects the results of this strategy, with the indicator reaching -0.73. Growth is supported by partnerships with pharma behemoths focusing on rare pathologies; however, the lack of revenue and dependence on R&D create risks of potential secondary offerings to fund laboratory operations.
Analytical breakdowns for Regulus Therapeutics, Inc. (RGLS)
- share price and expert price forecast:
- company stock exchange capitalization indicators:
- shareholders' equity book value data:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Regulus Therapeutics|RGLS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Regulus Therapeutics Inc|RGLS - Company Cumulative Debt|Debt to Book Capitalization Ratio Regulus Therapeutics Inc.|RGLS - Company Long-Term Loans and Borrowings|Company Short-Term Debts Regulus Therapeutics|Quick Liquidity regulusrx.com
- earnings and valuation multiples indicators:
RGLS - Profit After Tax|Projected Future Earnings Regulus Therapeutics|RGLS - Market Cap to Earnings|Projected Price to Earnings Regulus Therapeutics Inc.|RGLS - PEG Multiple|Enterprise Value to EBITDA Ratio Regulus Therapeutics Inc.|RGLS - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) Regulus Therapeutics|RGLS - Net earnings per share for the last four quarters|Quarterly EPS earnings growth regulusrx.com|RGLS - Net earnings per share growth this year|Net earnings per share growth forecast for next year Regulus Therapeutics
Basic company analysis:RGLS - Regulus Therapeutics
Long-term position planning requires an assessment of real business returns, excluding market noise. The specificity of Regulus Therapeutics (RGLS) lies in developing high-cost kidney therapies through strategic partnerships with pharmaceutical behemoths. By analyzing the chart of net profit per share over the last 12 months, an investor can see the final financial result allocated per share. This metric measures the actual efficiency of capitalizing scientific developments. The stability of this indicator confirms the financial resilience of Regulus Therapeutics (RGLS) during the intervals between clinical phases.
Competing companies
TEM: Net earnings per share for the last 12 months|QGEN - Net earnings per share (EPS TTM)|Ionis (IONS) - Earnings per share for the last twelve months|RGEN - Net earnings per share for the last four quarters|Net earnings per share for the last 12 months RNA|CRSP: Earnings per share for the trailing year|Net earnings per share for the last 12 months WGS (GeneDx Holdings Corp.)|Earnings per share for the last four quarters RARE|Net earnings per share (EPS TTM) BEAM (Beam Therapeutics)|Earnings per share for the trailing year SRPT|Twist Bio - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months 10x|Intellia Therapeutics (NTLA) - Earnings per share for the last twelve months|stoketherapeutics.com - Earnings per share for the trailing year|BLFS (BioLife Solutions) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Wave Life Sciences Ltd|Earnings per share for the last twelve months Maze Tx (MAZE)|SION: Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) PRME (Prime Medicine, Inc.)|tayshagtx.com (TSHA) - Net earnings per one share for the last twelve months|QURE: Net earnings per share for the last 12 months|MGTX - Net earnings per share (EPS TTM)|RGNX (Regenxbio) - Net earnings per share for the last 12 months|SLDB: Earnings per share for the last four quarters|OCGN (Ocugen, Inc.) - Net earnings per share (EPS TTM)|pacb.com (PACB) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) BNTC|Net earnings per share for the last 12 months Design Therapeutics Inc DSGN|Earnings per share for the last twelve months Rocket Pharmaceuticals Inc RCKT|Net earnings per share for the last four quarters 4D Molecular Corp (FDMT)|LXEO - Earnings per share for the last twelve months|Earnings per share for the trailing year KRRO (Korro Bio, Inc.)|EDIT: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Silence Therapeutics PLC SLN|Earnings per share for the last twelve months ProQR|Earnings per share for the last twelve months CDXS|Earnings per share for the last twelve months Sangamo Therapeutics (SGMO)|Net earnings per share for the last four quarters nautilus.bio|Net earnings per share (EPS TTM) MGX (Metagenomi)|DTIL: Earnings per share for the last 12 months|GBIO - Earnings per share for the last twelve months|BOLD (Boundless Bio Inc) - Earnings per share for the last 12 months|XCUR: Net earnings per share (EPS TTM)|Imunon (IMNN) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Phio Pharmaceuticals Corp|MBIO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RNAZ|BNGO - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) APDN (Applied DNA Sciences)|Net earnings per share for the trailing year bluebirdbio.com|IPA: Net earnings per share for the last 12 months|OMGA - Net earnings per share (EPS TTM)|Singular Genomics Systems Inc (OMIC) - Earnings per share for the last twelve months|SYRS (Syros Pharmaceuticals, Inc) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months TBIO|Net earnings per share (EPS TTM) traconpharma.com|Earnings per share for the last twelve months Unity Biotechnology, Inc. (UBX)
